Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator‐controlled, double‐blind study
Year: 2012
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Diabetes Obesity and Metabolism
Authors: R. Kawamori, N. Inagaki, E. Araki, H. Watada, N. Hayashi, Y. Horie, A. Sarashina, Y. Gong, M. von Eynatten, H. J. Woerle, K. A. Dugi
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funders: Eli Lilly and Company, Novo Nordisk
OpenAlex ID: W2109911153
